Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
Stealth Biotherapeutics Announces Data from ReCLAIM-2 Phase 2 Trial of Elamipretide in Geographic Atrophy
Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation
No events listed at this time.
@StealthBT on Twitter
275 Grove Street, Suite 3-107
Newton, MA 02466